FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313144719> ?p ?o ?g. }

• W4313144719 abstract "Objectives. As asthma is a chronic inflammatory disease of the airways, anti‑inflammatory treatment should bepositioned at the forefront of guideline-directed asthma care. However, patients tend to rely on short-acting β2-agonists (SABAs) for rapid-onset symptom relief. The impact of SABA overuse and associated clinical outcomeshave been investigated extensively in Europe and North America. Limited data are available from countries in Asia, Africa, Latin America, and the Middle East. The SABA use IN Asthma (SABINA) III program, a large multicountry, observational study, was undertaken to describe the global extent of SABA use and its potential contribution to suboptimal disease control. As part of the SABINA III study, we aimed to characterize SABA prescription collection and asthma-related clinical outcomes among patients in the Philippines.Methods. This nationwide, observational, cross-sectional, SABINA III study included patients (aged ≥12 years) with a documented asthma diagnosis recruited between May 2019 and January 2020 from 10 sites in the Philippines. Demographics, disease characteristics and prescribed asthma treatments, including SABA and inhaled corticosteroids (ICS) in the 12 months preceding study start, were recorded during a single visit, and transcribed onto an electronic case report form (eCRF). Patients were classified by investigator‑defined asthma severity, guided by the 2017 Global Initiative for Asthma (GINA) report and practice type, either primary or pulmonary medicine specialist care.Results. Of 245 patients analyzed, 63.3% were classified as having moderate-to-severe asthma (GINA steps 3−5), and most patients (63.3%) were enrolled by pulmonary medicine specialists. Overall, 33.1% (n=81) of patients had experienced ≥1 severe exacerbation in the previous 12 months and 18.4% (n=45) of patients had uncontrolled asthma. With respect to asthma treatments, a total of 6.5% (n=16), 40.4% (n=99), and 2.4% (n=6) of patients were prescribed SABA monotherapy, SABA in addition to maintenance therapy, and ICS, respectively, in the 12 months prior to their study visit. Most patients (n=156 [63.7%]) received prescriptions of fixed‑dose combinations of ICS and long-acting β2-agonists. SABA over-prescription, defined as ≥3 SABA canister prescriptions per year, was observed in 10.6% (n=21) of patients. Additionally, 25.6% (n=23) ofpatients classified as having mild asthma were prescribed either nebulized SABA (n=17) or oral SABA (n=6). Nearly one-third of patients (n=75 [30.6%]) had purchased over-the-counter (OTC) SABA, and 46.9% (n=115) were prescribed antibiotics.Conclusions. In this SABINA III Philippines study cohort, more than 10% of patients were over-prescribed SABAcanisters. Additionally, prescriptions for oral or nebulized SABA, the purchase of non-prescription (OTC) SABA,and the high percentage of prescriptions for antibiotics warrant country-wide improvements in asthma care and management." @default.
• W4313144719 created "2023-01-06" @default.
• W4313144719 date "2022-01-01" @default.
• W4313144719 modified "2023-10-16" @default.
• W4313144719 title "Short-acting β2-agonist Prescription Patterns in Patients with Asthma in the Philippines: Results from SABINA III" @default.
• W4313144719 doi "https://doi.org/10.47895/amp.vi0.4816" @default.
• W4313144719 hasPublicationYear "2022" @default.
• W4313144719 type Work @default.
• W4313144719 citedByCount "0" @default.
• W4313144719 crossrefType "journal-article" @default.
• W4313144719 hasBestOaLocation W43131447191 @default.
• W4313144719 hasConcept C126322002 @default.
• W4313144719 hasConcept C142724271 @default.
• W4313144719 hasConcept C144024400 @default.
• W4313144719 hasConcept C149923435 @default.
• W4313144719 hasConcept C170493617 @default.
• W4313144719 hasConcept C187212893 @default.
• W4313144719 hasConcept C23131810 @default.
• W4313144719 hasConcept C2426938 @default.
• W4313144719 hasConcept C2776042228 @default.
• W4313144719 hasConcept C2779134260 @default.
• W4313144719 hasConcept C2779591629 @default.
• W4313144719 hasConcept C2780084366 @default.
• W4313144719 hasConcept C2780182762 @default.
• W4313144719 hasConcept C2991922776 @default.
• W4313144719 hasConcept C3017940444 @default.
• W4313144719 hasConcept C512399662 @default.
• W4313144719 hasConcept C71924100 @default.
• W4313144719 hasConcept C98274493 @default.
• W4313144719 hasConceptScore W4313144719C126322002 @default.
• W4313144719 hasConceptScore W4313144719C142724271 @default.
• W4313144719 hasConceptScore W4313144719C144024400 @default.
• W4313144719 hasConceptScore W4313144719C149923435 @default.
• W4313144719 hasConceptScore W4313144719C170493617 @default.
• W4313144719 hasConceptScore W4313144719C187212893 @default.
• W4313144719 hasConceptScore W4313144719C23131810 @default.
• W4313144719 hasConceptScore W4313144719C2426938 @default.
• W4313144719 hasConceptScore W4313144719C2776042228 @default.
• W4313144719 hasConceptScore W4313144719C2779134260 @default.
• W4313144719 hasConceptScore W4313144719C2779591629 @default.
• W4313144719 hasConceptScore W4313144719C2780084366 @default.
• W4313144719 hasConceptScore W4313144719C2780182762 @default.
• W4313144719 hasConceptScore W4313144719C2991922776 @default.
• W4313144719 hasConceptScore W4313144719C3017940444 @default.
• W4313144719 hasConceptScore W4313144719C512399662 @default.
• W4313144719 hasConceptScore W4313144719C71924100 @default.
• W4313144719 hasConceptScore W4313144719C98274493 @default.
• W4313144719 hasLocation W43131447191 @default.
• W4313144719 hasOpenAccess W4313144719 @default.
• W4313144719 hasPrimaryLocation W43131447191 @default.
• W4313144719 hasRelatedWork W1599491162 @default.
• W4313144719 hasRelatedWork W1988146217 @default.
• W4313144719 hasRelatedWork W2011872649 @default.
• W4313144719 hasRelatedWork W2041632375 @default.
• W4313144719 hasRelatedWork W2764198422 @default.
• W4313144719 hasRelatedWork W2949087050 @default.
• W4313144719 hasRelatedWork W3022420392 @default.
• W4313144719 hasRelatedWork W3046881141 @default.
• W4313144719 hasRelatedWork W4283076903 @default.
• W4313144719 hasRelatedWork W4313144719 @default.
• W4313144719 isParatext "false" @default.
• W4313144719 isRetracted "false" @default.
• W4313144719 workType "article" @default.